Michael Saylor says quantum computing poses no threat to Bitcoin for over 10 years, calling concerns FUD. BTC falls below $65K amid Trump tariff anxiety.
Browsing: News
Seeker (SKR) rallied 65% after Upbit, South Korea’s top crypto exchange, listed the token. Volume surged 317% as the price climbed from $0.018 to $0.032.
Dogecoin (DOGE) drops below $0.10 as a rare cycle indicator hits record highs. The same signal previously triggered rallies of 65,000% and 750%.
Backpack Exchange announces token-to-equity conversion program, reserving 20% company ownership for stakers as it pursues $50M funding at $1B valuation.
Bitcoin trades at $62,900, down 7.5% weekly, as AI disruption fears trigger selloffs across crypto and stock markets. Altcoins face intense pressure.
Solana (SOL) trades near $77 after hitting $75.80, leaving 80% of holders at a loss. Funding rates turn negative as bearish pressure mounts.
Step Finance shuts down permanently after losing $27M in a January hack. STEP token crashes 96%. Details on token buybacks and what comes next.
Terraform’s bankruptcy trustee accuses Jane Street of insider trading during the 2022 Terra collapse, claiming the firm used confidential data to dump tokens.
XRP faces technical headwinds with a bearish chart pattern forming while whales deposit over 31M tokens to Binance. Support at $1.22 under watch.
Bitcoin falls below $63,000 as whale selling intensifies and Trump tariffs shake markets. Analysts now eyeing $50K support level amid extreme fear.
Ethereum tests a crucial 5-year demand zone at $1,820. Analysts spot bullish divergence while bears target $1,740. BitMine adds 51,162 ETH this week.
Anthropic’s Claude Code COBOL automation crushed IBM stock by 11% and pushed Bitcoin to $62,700. Analysis of the February 23, 2026 market impact.
Domino’s Pizza stock surged 6% after Q4 revenue topped $1.54B, U.S. same-store sales exceeded forecasts, and the company announced a 14.4% dividend hike.
Wells Fargo keeps Overweight on CoreWeave (CRWV) at $125 target, signaling estimates may be low ahead of Q4 earnings Feb 26 with $1.57B revenue projected.
Novo Nordisk stock plummeted 15% after CagriSema failed to match Eli Lilly’s tirzepatide in clinical trial, marking another setback for the drugmaker.